Showing results (91-100 of 155) with videos related to
Sort By:
Pageof 16
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.The European Respiratory Journal|September 19, 2015
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504Jacques Cadranel, Radj Gervais, Patrick Merle, et al.British Journal of Cancer|February 12, 2019
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trialElodie Maille, Solenn Brosseau, Vincent Hanoux, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCMark A Socinski, Makoto Nishio, Robert M Jotte, et al.Clinical Lung Cancer|July 8, 2019
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS CohortSolenn Brosseau, Claire Danel, Arnaud Scherpereel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung CancerMartin Reck, Thomas Wehler, Francisco Orlandi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.Molecular Cancer Therapeutics|March 14, 2012
High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathwayGuénaëlle Levallet, Emmanuel Bergot, Martine Antoine, et al.Pageof 16